Focus Partners Wealth Acquires 8,839 Shares of Amgen Inc. $AMGN

Key Points

• Focus Partners Wealth increased its stake in Amgen (AMGN) by 4.0%, buying 8,839 shares to hold 228,021 shares valued at about $64.32 million as of the Q3 13F filing.
• Amgen beat expectations with $5.29 EPS vs $4.76 est and $9.87B revenue vs $9.46B, set FY2026 guidance of $21.60–$23.00 EPS, and announced a $2.52 quarterly dividend ($10.08 annual, ~2.8% yield).

Focus Partners Wealth grew its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 228,021 shares of the medical research company's stock after buying an additional 8,839 shares during the quarter. Focus Partners Wealth's holdings in Amgen were worth $64,321,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Elevation Point Wealth Partners LLC boosted its position in shares of Amgen by 626.6% during the 3rd quarter. Elevation Point Wealth Partners LLC now owns 6,227 shares of the medical research company's stock valued at $1,757,000 after acquiring an additional 5,370 shares in the last quarter. Bollard Group LLC raised its position in Amgen by 0.8% in the third quarter. Bollard Group LLC now owns 3,931 shares of the medical research company's stock worth $1,109,000 after purchasing an additional 33 shares in the last quarter. Circle Wealth Management LLC lifted its stake in Amgen by 7.7% during the third quarter. Circle Wealth Management LLC now owns 1,570 shares of the medical research company's stock worth $443,000 after purchasing an additional 112 shares during the period. Clark Capital Management Group Inc. lifted its stake in Amgen by 19.8% during the third quarter. Clark Capital Management Group Inc. now owns 1,103 shares of the medical research company's stock worth $311,000 after purchasing an additional 182 shares during the period. Finally, Community Bank N.A. boosted its holdings in Amgen by 1.0% during the third quarter. Community Bank N.A. now owns 16,270 shares of the medical research company's stock valued at $4,591,000 after purchasing an additional 161 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 0.0%

NASDAQ AMGN opened at $366.25 on Tuesday. The stock's 50 day simple moving average is $358.64 and its 200 day simple moving average is $326.25. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The firm has a market cap of $197.43 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 3.63 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen's dividend payout ratio is 70.84%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group increased their target price on Amgen from $403.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, February 4th. Citigroup boosted their price target on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a research note on Wednesday, February 4th. Wells Fargo & Company upped their price target on Amgen from $325.00 to $375.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. Cantor Fitzgerald increased their price objective on Amgen from $315.00 to $350.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. Finally, UBS Group boosted their target price on shares of Amgen from $380.00 to $390.00 and gave the company a "buy" rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of "Hold" and an average price target of $354.00.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.